How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

279 results for

Hemorrhoid Coagulation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Snake Envenomation, Mohave Rattle (Follow-up)

clinical course. When considering the use of antivenom, weigh the risk of adverse reaction to antivenom against the benefits of reducing venom toxicity. Nonenvenomation, ie, dry bite (probably occurs in < 10% of rattlesnake bites), is characterized by the following: Local effects - Puncture wounds only Systemic effects - None Coagulation abnormalities - No laboratory evidence of coagulation abnormalities and no clinical evidence of abnormal bleeding or clotting Minimal or mild envenomation (...) is characterized by the following: Local effects - Swelling, pain, tenderness, and/or ecchymosis confined to the immediate bite area Systemic effects - None Coagulation abnormalities - No laboratory evidence of coagulation abnormalities and no clinical evidence of abnormal bleeding or clotting Moderate envenomation is characterized by the following: Local effects - Swelling, pain, tenderness, and/or ecchymosis extending beyond the immediate bite area but involving less than the entire part Systemic effects

2014 eMedicine Emergency Medicine

202. Snake Envenomation, Moccasins (Follow-up)

to be dead. Do not reach or step into places outdoors that are not visible. At home, remove debris in which snakes might hide (eg, log piles). Remove items, such as bird feeders, that might attract snakes—seeds that fall from bird feeders attract rodents, which attract snakes. Heavy clothing (such as hiking boots) may retard some strikes. Young children should be closely supervised, and older children should be educated to avoid snakes. [ ] Previous Next: Long-Term Monitoring Discharge instructions (...) for 2 weeks after the snakebite. Drink plenty of liquids. Return if urine decreases in amount or becomes cola colored. Referral to a physical therapist or surgeon may be indicated. Patients who developed severe coagulopathy or thrombocytopenia should have these studies rechecked in 3 days, and as needed for signs of coagulation problems (eg, bleeding gums, easy bruising). Previous References Wingert WA, Pattabhiraman TR, Cleland R, Meyer P, Pattabhiraman R, Russell FE. Distribution and pathology

2014 eMedicine Emergency Medicine

203. Thrombophlebitis, Superficial (Follow-up)

is present in an affected area. [ ] In the case of thrombosis of a hemorrhoid, evacuation of the thrombus, though very painful, usually provides rapid relief. Magnesium sulfate compresses may also be used to alleviate swelling and pain, though surgery is sometimes necessary to remove the clot from the hemorrhoid. Next: Compression Stockings Long-leg, heavy-gauge elastic stockings or multiple elastic (Ace) bandages are indicated when the patient becomes ambulatory. Gradient compression stockings (...) compressibility of vein secondary to intraluminal thrombus. Courtesy of Wikimedia Commons ©Nevit Dilmen. Blood coagulation (thrombin) and protein C pathways. Courtesy of Wikimedia Commons ©John H Griffin, PhD. of 3 Tables Contributor Information and Disclosures Author Khanjan H Nagarsheth, MD, MBA Assistant Professor of Surgery, Department of Vascular Surgery, University of Maryland Medical System Khanjan H Nagarsheth, MD, MBA is a member of the following medical societies: Academic Surgical Congress

2014 eMedicine Emergency Medicine

204. Deep Venous Thrombosis and Thrombophlebitis (Overview)

) are required The main laboratory studies to be considered include the following: D-dimer testing Coagulation studies (eg, prothrombin time and activated partial thromboplastin time) to evaluate for a hypercoagulable state See for more detail. Management Treatment options for DVT include the following: Anticoagulation (mainstay of therapy) - Heparins, warfarin, factor Xa inhibitors, and various emerging anticoagulants Pharmacologic thrombolysis Endovascular and surgical interventions Physical measures (eg (...) thrombosis in the legs and PE. DVT is the presence of coagulated blood, a thrombus, in one of the deep venous conduits that return blood to the heart. The clinical conundrum is that symptoms (pain and swelling) are often nonspecific or absent. However, if left untreated, the thrombus may become fragmented or dislodged and migrate to obstruct the arterial supply to the lung, causing potentially life-threatening PE See the images below. Venous thrombus. Pulmonary embolus. DVT most commonly involves

2014 eMedicine Emergency Medicine

205. Anemia, Acute (Overview)

intravenous (IV) sites and mucous membranes may be due to disseminated intravascular coagulation (DIC). Patients with alcoholic liver disease may have spider angiomata, caput medusae, umbilical hernias, and hemorrhoids. Acute blood loss may result in agitation. When blood loss exceeds 40% of total volume, the patient may lose consciousness. With chronic anemia, the patient may have a hyperdynamic heart, with a prominent point of maximal impulse (PMI), a systolic flow murmur, and occasionally an S 3 (...) (TTP) is rare. Arteriolar lesions with localized platelet thrombi and fibrin deposits lead to thrombocytopenia and hemolytic anemia. The tissue hypoxia from occlusion of the vessels in the affected organ causes the symptoms of TTP. However, the cause of the occlusion remains unknown. Microangiopathic hemolytic anemia, thrombocytopenia, normal coagulation test results, and renal and neurologic abnormalities should lead the physician to the diagnosis. (ITP) is an autoimmune disease often precipitated

2014 eMedicine Emergency Medicine

206. Anemia, Acute (Follow-up)

intravenous (IV) sites and mucous membranes may be due to disseminated intravascular coagulation (DIC). Patients with alcoholic liver disease may have spider angiomata, caput medusae, umbilical hernias, and hemorrhoids. Acute blood loss may result in agitation. When blood loss exceeds 40% of total volume, the patient may lose consciousness. With chronic anemia, the patient may have a hyperdynamic heart, with a prominent point of maximal impulse (PMI), a systolic flow murmur, and occasionally an S 3 (...) (TTP) is rare. Arteriolar lesions with localized platelet thrombi and fibrin deposits lead to thrombocytopenia and hemolytic anemia. The tissue hypoxia from occlusion of the vessels in the affected organ causes the symptoms of TTP. However, the cause of the occlusion remains unknown. Microangiopathic hemolytic anemia, thrombocytopenia, normal coagulation test results, and renal and neurologic abnormalities should lead the physician to the diagnosis. (ITP) is an autoimmune disease often precipitated

2014 eMedicine Emergency Medicine

207. Anemia, Acute (Treatment)

intravenous (IV) sites and mucous membranes may be due to disseminated intravascular coagulation (DIC). Patients with alcoholic liver disease may have spider angiomata, caput medusae, umbilical hernias, and hemorrhoids. Acute blood loss may result in agitation. When blood loss exceeds 40% of total volume, the patient may lose consciousness. With chronic anemia, the patient may have a hyperdynamic heart, with a prominent point of maximal impulse (PMI), a systolic flow murmur, and occasionally an S 3 (...) (TTP) is rare. Arteriolar lesions with localized platelet thrombi and fibrin deposits lead to thrombocytopenia and hemolytic anemia. The tissue hypoxia from occlusion of the vessels in the affected organ causes the symptoms of TTP. However, the cause of the occlusion remains unknown. Microangiopathic hemolytic anemia, thrombocytopenia, normal coagulation test results, and renal and neurologic abnormalities should lead the physician to the diagnosis. (ITP) is an autoimmune disease often precipitated

2014 eMedicine Emergency Medicine

208. Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

) at the first screening examination Exclusion Criteria: Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal Known coagulation disorders (eg von Willebrand's disease, hemophilia) Known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer) Known sensitivity to common causes of bleeding (eg nasal) Regular use of medicines Clinically (...) Research & Development, LLC Information provided by (Responsible Party): Bayer Study Details Study Description Go to Brief Summary: Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders. Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels. Excessive coagulation activity can occur in children as well, and rivaroxaban is therefore being developed for the treatment of thromboembolic events in children and adolescents

2013 Clinical Trials

209. Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

Last Update Posted : October 2, 2017 Sponsor: Perosphere, Inc. Information provided by (Responsible Party): Perosphere, Inc. Study Details Study Description Go to Brief Summary: PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977 that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care prothrombin time [PoC-PT]), and/or secondary (...) Laboratory values (chemistry, complete blood count coagulation assessments) and urinalysis performed during screening up to 21 days prior to administration of study treatment are within normal limits. No clinically significant findings on 12-lead electrocardiogram (ECG) performed during screening. Body mass index (BMI) 18 to ≤32 kg/m2, inclusive Male subjects agree to use appropriate contraception (i.e., double barrier contraception such as a latex condom with spermicide with a female partner of child

2013 Clinical Trials

210. Antithrombotic Triple Therapy in Humans

of efficacy or safety data for the combined impact of antithrombotic drugs in patients requiring arterial and venous thromboembolic prophylaxis due to their underlying co-morbidities. Study objectives: To evaluate the effect of ticagrelor + ASA in combination with dabigatran, rivaroxaban or phenprocoumon at steady state on markers of coagulation activation. The effects on coagulation activation will also be studied after a single dose of dabigatran, rivaroxaban or ticagrelor and at a therapeutic INR (...) of phenprocoumon. Study design: A single-centre, prospective, randomized, controlled, analyst-blinded study in three parallel-groups. Subjects will receive ticagrelor + ASA in combination with dabigatran (treatment A), rivaroxaban (treatment B) or phenprocoumon (treatment C). All IMPs will be administered at doses indicated for stroke prevention in AF or ACS. Markers on thrombin generation and platelet activation will be studied in venous blood where coagulation is in resting state and in shed blood where

2013 Clinical Trials

211. A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

procoagulant markers D dimer [ Time Frame: Day 1 ] To evaluate the effects of Beriplex P/N following 60 mg edoxaban on the procoagulant markers D dimer and prothrombin fragment F1 + 2 (F1 + 2) prothrombin fragment F1 + 2 [ Time Frame: Day 1 ] To evaluate the effects of Beriplex P/N following 60 mg edoxaban on the procoagulant markers D dimer and prothrombin fragment F1 + 2 (F1 + 2) coagulation factor concentrations [ Time Frame: Day 1 ] To evaluate the effects of Beriplex P/N following 60 mg edoxaban (...) on coagulation factor concentrations cmax of edoxaban and its active metabolite, D21-2393 [ Time Frame: Day 1 ] To evaluate single dose pharmacokinetics (PK) of edoxaban and its active metabolite, D21-2393 tmax of edoxaban and its active metabolite, D21-2393 [ Time Frame: Day 1 ] To evaluate single dose pharmacokinetics (PK) of edoxaban and its active metabolite, D21-2393 AUC 0-24 of edoxaban and its active metabolite, D21-2393 [ Time Frame: Day 1 ] To evaluate single dose pharmacokinetics (PK) of edoxaban

2013 Clinical Trials

212. An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing

Visible fibers of the internal sphincter were seen at the base of the fissure or if a sentinel pile was present. VAS of > 35 mm in screening visit If female, is non-lactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to entry to the study or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual (...) hypertension (sitting blood pressure <160/95 mmHg at screening) History of chronic gastrointestinal disease. History of rectal surgery. History of gastrointestinal surgery. History of HIV, hepatitis B, hepatitis C. In need of chronic use of medication, with the exception of birth control medications. Currently uses medication for acute illness (other than medications for use of treatment/pain relief of anal fissure). Has used, in the last two weeks, drugs that may affect blood coagulation, such as Aspirin

2013 Clinical Trials

213. Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

, coagulation, urinalysis, and serology. Male subjects, and their partners, agree to use contraception throughout the study duration. Male subjects must use 1 barrier method of contraception and spermicide during the trial, and for 3 months after the last dose of study drug. Male subjects with female partners of child-bearing potential must also agree to use an additional highly effective method of contraception. They must use a condom, and their female partners must use an additional method (...) history of any of the following gastrointestinal (GI) diseases: intestinal obstruction, chronic or severe constipation, subileus, ileus, intestinal stenosis, intestinal diverticulosis and/or diverticulitis, colitis, GI ulcers, recent major GI surgery, peritonitis, GI bleeding, gastritis, haemorrhoids, or any other severe GI disease. Current or any history of biliary obstruction, cholestasis, or severe hepatic impairment. Current or history of seizure disorders. Current or history of Vitamin K

2013 Clinical Trials

214. Portal pyaemia secondary to open haemorrhoidectomy: need for prophylactic broad spectrum antibiotics Full Text available with Trip Pro

Portal pyaemia secondary to open haemorrhoidectomy: need for prophylactic broad spectrum antibiotics A 70-year-old man presenting with long standing grade 3 Haemorrhoids, underwent open haemorrhoidectomy under spinal anaesthesia. The patient passed stools on subsequent day and there was no bleeding per rectum. On day 5, he complained of dull aching upper abdominal pain. On physical examination, the abdomen was soft and there was mild tenderness in the epigastric region. Subsequently, he (...) developed high temperature with chills and rigors. His condition failed to improve and the abdominal pain increased in severity. There was no pain in the perianal region and per rectum examination was normal. Leucocyte count rose to 12×10(9)/L and there were toxic changes on peripheral smear. Blood culture grew Staphylococcus aureus. Liver enzymes were mildly elevated. Coagulation profile was deranged. Fibrin degradation products were positive. D-dimer was high. CT revealed acute thrombosis of left

2013 BMJ case reports

215. Anfibatide Phase 1 Clinical Trial in Healthy Volunteers

Study Description Go to Brief Summary: In this 94 healthy subjects Phase I clinical trial, we assess the clinical profile of Anfibatide, a specific glycoprotein Ib antagonist. This study represents the first clinical evidence that Anfibatide exhibits strong anti-platelet effects, excellent reversibility, and low bleeding potential in healthy human subjects. Condition or disease Intervention/treatment Phase Coronary Heart Disease Coagulation Disorder Drug: Anfibatide Phase 1 Study Design Go to Layout (...) medical history: no history of heart, liver, kidney, digestive tract, nervous system and metabolic disorder, or ulcer, significant hemorrhage, without the history of drug allergy and postural hypotension; 4) Medical examinations: with normal results in overall examinations (including heart rate, blood pressure, auscultation of heart and lung, palpation of liver and spleen, hepatic and renal function, hematology, coagulation function, urine analysis, stool analysis and occult blood test

2012 Clinical Trials

216. Phase 1 Single Dose Escalation Study of CTB-001

disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or cognitive disorders. History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion. History of known hypersensitivity to drugs including CTB-001 Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff (...) Drug: CTB-001 IV bolus or IV infusion Outcome Measures Go to Primary Outcome Measures : Safety [ Time Frame: Up to 7 hours ] Summary statistics for SAD parts will be prepared for measured values and changes from baseline values for each dose group. Placebo subjects will serve as the control. Summaries of treatment-emergent and clinically important abnormalities in ECG, physical examination, vital signs, and laboratory (clinical chemistry, hematology, coagulation, urinalysis) data will be provided

2012 Clinical Trials

217. Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

to men, and only to women who opt for rectal sampling: Abnormalities of the colorectal mucosa or significant colorectal symptom(s), which in the opinion of the study investigator represent a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids) Per participant report at screening, anticipated use and/or unwillingness to abstain from the following (...) days prior to rectal biopsies and for 7 days after biopsies Per participant report at screening, anticipated use and/or unwillingness to abstain from the following medications for a period of 10 days before a biopsy procedure: aspirin (daily use of low-dose aspirin [no more than 81 mg] is allowed at the discretion of the Investigator of Record) or non-steroidal anti-inflammatory drugs (NSAIDS) Abnormal laboratory results for coagulation tests that may indicate an increased risk of bleeding

2012 Clinical Trials

218. Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

the study and up to 90 days after their last dose of study drug. Exclusion Criteria: History of malignant disease, including solid tumors and hematologic malignancies. Clinically significant current active infection or serious infection. History of gastrointestinal bleeding, peptic ulcer disease, hemorrhoids or epistaxis. Personal or family history of any bleeding disorder, and/or coagulation profile results outside of normal limits. Known allergy or hypersensitivity to warfarin. Contacts and Locations

2012 Clinical Trials

220. Surgery in haemophilia and allied disorders. Full Text available with Trip Pro

Surgery in haemophilia and allied disorders. 4922847 1971 02 09 2018 11 13 0035-8843 47 3 1970 Sep Annals of the Royal College of Surgeons of England Ann R Coll Surg Engl Surgery in haemophilia and allied disorders. 125-38 Anscombe A R AR eng Historical Article Journal Article England Ann R Coll Surg Engl 7506860 0035-8843 0 Blood Coagulation Factors 9001-27-8 Factor VIII IM Q Abdomen, Acute surgery Blood Coagulation Blood Coagulation Factors Blood Platelets Factor VIII therapeutic use Female (...) Hematemesis surgery therapy Hematoma surgery Hemophilia A history surgery Hemophilia B surgery Hemorrhoids surgery therapy History, 18th Century History, 19th Century History, 20th Century Humans Male Melena surgery therapy Peptic Ulcer surgery therapy 1970 9 1 1970 9 1 0 1 1970 9 1 0 0 ppublish 4922847 PMC2387787 Br Med J. 1952 Dec 27;2(4799):1378-82 12997790 N Engl J Med. 1965 Dec 30;273(27):1443-7 5852902 Science. 1936 Sep 18;84(2177):270-1 17742899 Lancet. 1965 Nov 20;2(7421):1036-9 4159132 Proc Soc

1970 Annals of the Royal College of Surgeons of England

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>